The Clinical Utilisation and Duration of Treatment with HER2-Directed Therapies in HER2-Positive Recurrent or Metastatic Salivary Gland Cancers
Current Oncology · 2024
DOI: 10.3390/curroncol31090419 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Current Oncology, 2024. Verfasst von Joseph Edward Haigh und 6 weiteren Autor:innen. Beteiligte Einrichtung: The Christie NHS Foundation Trust, Wilmslow Road Manchester, Manchester M20 4BX, UK. Hauptthemen laut MEDLINE: Salivary Gland Neoplasms, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Christie Charity, Syncona Foundation, The Infrastructure Industry Foundation.
Abstract (Originalsprache)
Salivary gland cancers (SGC) are rare tumours with limited availability of systemic therapies. Some SGC subtypes overexpress HER2, and this represents a potential therapeutic target, but the evidence base is limited. This study sought to analyse real-world data on the efficacy of HER2-directed therapies in SGC. This is a retrospective observational study using anonymised data from commercial compassionate-use access registrations and a privately funded pharmacy prescribing register. Treatment duration was defined as the time from drug initiation to treatment discontinuation. Kaplan–Meier analysis of treatment duration was performed using R for Windows (v4.3.2). A case report is also provided of an exceptional responder. Eighteen patients were identified who received HER2-directed therapies for HER2-positive recurrent/metastatic SGC, and complete data on treatment duration was available for 15/18. Histology was salivary duct carcinoma in 13/18 patients, adenocarcinoma NOS in 4/18, and carcinoma ex pleomorphic adenoma in 1/18. The median treatment duration was 8.3 months (95% CI: 6.41-not reached), and the range was 1.0–47.0 months. Choice of HER2-directed therapy varied, with ado-trastuzumab emtasine being the most common (9/18). At the time of analysis, HER2-directed therapy was ongoing for 9/15, discontinued due to disease progression for 4/15, discontinued due to toxicity for 1/15, and 1/15 was discontinued for an unspecified reason. An exceptional responder experienced a complete response with a treatment duration of 47.0 months. These real-world data are comparable to the median PFS observed with HER2-directed therapies in phase II trials and support the use of HER2-directed therapies in this group.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Christie NHS Foundation Trust, Wilmslow Road Manchester, Manchester M20 4BX, UK.
- The Royal Marsden NHS Foundation Trust, Fulham Road, London SW3 6JJ, UK.
- Department of Medicine, Universidad Autónoma de Barcelona, Plaça Cívica, Bellaterra, 08193 Barcelona, Spain.
- The Institute of Cancer Research, Division of Radiotherapy and Imaging, 123 Old Brompton Road, London SW7 3RP, UK.
- Manchester University NHS Foundation Trust, Oxford Road, Manchester M13 9WL, UK.
ORCID-Profile: Joseph Edward Haigh, Guy Betts
Förderung
- The Christie Charity
- Syncona Foundation
- The Infrastructure Industry Foundation
Zitieren
APA
Haigh, J. E., Patel, K., Rack, S., Jiménez-Labaig, P., Betts, G., Harrington, K. J., & Metcalf, R. (2024). The Clinical Utilisation and Duration of Treatment with HER2-Directed Therapies in HER2-Positive Recurrent or Metastatic Salivary Gland Cancers. Current Oncology. https://doi.org/10.3390/curroncol31090419
Vancouver
Haigh JE, Patel K, Rack S, Jiménez-Labaig P, Betts G, Harrington KJ, et al. The Clinical Utilisation and Duration of Treatment with HER2-Directed Therapies in HER2-Positive Recurrent or Metastatic Salivary Gland Cancers. Current Oncology. 2024. doi:10.3390/curroncol31090419
BibTeX
@article{Haigh2024,
author = {Haigh, Joseph Edward and Patel, Karan and Rack, Sam and Jiménez-Labaig, Pablo and Betts, Guy and Harrington, Kevin Joseph and Metcalf, Robert},
title = {The Clinical Utilisation and Duration of Treatment with HER2-Directed Therapies in HER2-Positive Recurrent or Metastatic Salivary Gland Cancers},
journal = {Current Oncology},
year = {2024},
doi = {10.3390/curroncol31090419}
}
EUVIMED